CoChat
Sign Up
Cited by 314Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorMental Health and Psychiatry

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol

Keefe, Richard S.E., Seidman, Larry J., Christensen, Bruce K., Hamer, Robert M., Sharma, Tonmoy, Sitskoorn, Margriet M., Lewine, Richard R.J., Yurgelun-Todd, Deborah A., Gur, Ruben C., Tohen, Mauricio, Tollefson, Gary D., Sanger, Todd M., Lieberman, Jeffrey A., HGDH Research Group·2004·American Journal of Psychiatry
DOI 10.1176/appi.ajp.161.6.985
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. METHOD: Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9.63 mg/day) or haloperidol (mean modal dose=4.60 mg/day) for the 12-week acute phase of a 2-year study. The patients were assessed with a battery of neurocognitive tests at baseline and 12 weeks after beginning treatment. RESULTS: An unweighted neurocognitive composite score, composed of measures of verbal fluency, motor functions, working memory, verbal memory, and vigilance, improved significantly with both haloperidol and olanzapine treatment (effect sizes of 0.20 and 0.36, respectively, no significant difference between groups). A weighted composite score developed from a principal-component analysis of the same measures improved to a significantly greater degree with olanzapine, compared with haloperidol. Anticholinergic use, extrapyramidal symptoms, and estimated IQ had little effect on the statistical differentiation of the medications, although duration of illness had a modest effect. The correlations of cognitive improvement with changes in clinical characteristics and with side effects of treatment were significant for patients who received haloperidol but not for patients who received olanzapine. CONCLUSIONS: Olanzapine has a beneficial effect on neurocognitive function in patients with a first episode of psychosis. However, in a comparison of the effects of olanzapine and low doses of haloperidol, the difference in benefit is small.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.161.6.985

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 47 references

1 of the 47 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 301–314 of 314

Related

See all

Metadata

Authors
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., Tollefson, G. D., Sanger, T. M., Lieberman, J. A., & HGDH Research Group
Affiliations
Duke University (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2004-06-01
Volume
161
Issue
6
Pages
985-995
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.161.6.985
OpenAlex
W2145453003
Cited by
314
References
47
Citations by year
2026: 1 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 14 · 2012: 12
FWCI
24.47
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
olanzapine, haloperidol, first-episode psychosis, neurocognitive function, atypical antipsychotics, typical antipsychotics, schizophrenia, schizoaffective disorder, verbal fluency, working memory, verbal memory, sustained attention, anticholinergic effects, extrapyramidal symptoms, IQ, disease duration
MeSH terms
Olanzapine, Adolescent, Adult, Basal Ganglia Diseases, Benzodiazepines, Cognition Disorders, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Haloperidol, Humans, Male, Neuropsychological Tests, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Principal Component Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review